Clinical trial · Interventional
Brazilian Lung Immunotherapy Study
Evaluation of Costs and Outcomes of the Implementation of Treatment Protocol Based on Rational Utilization of Anti-PD1 Agents in Patients With Non-small-cell Lung Cancer in the Brazilian Public Health System
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Immunotherapy with anti-PD-1/PD-L1 agents either as single agents or combined with chemotherapy is now considered the standard of care for patients with non-small-cell lung cancer. However, it has not been incorporated in the Brazilian Public Health System because of concerns about patient eligibility, safety and costs. It is known that simple biomarkers can be used to select patients for immunotherapy, such as EGRF, ALK and PD-L1 status in the tumors. We created a treatment protocol based on these 3 markers and treated 154 patients with non-small-cell-lung cancer in a Public Hospital in Brazil. The goal of this project is to identify the prevalence of these markers in the Brazilian population (to estimate patient eligibility), outcomes and costs of therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Neoplasm | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Alectinib | Drug | Alectinib | ALIAS |
| Erlotinib | Drug | Erlotinib | ALIAS |
| Nivolumab | Drug | Nivolumab | ALIAS |
| Pembrolizumab | Drug | Pembrolizumab | ALIAS |
Design
Arms and outcomes
Arms (4)
- type
- ACTIVE_COMPARATOR
- label
- ALK-translocated
- description
- 1. st line Alectinib 2. nd line Carboplatin pemetrexed 3. rd line Docetaxel
- interventionNames
- Drug: Alectinib
- type
- ACTIVE_COMPARATOR
- label
- EGFR-mutant
- description
- 1. st line Erlotinib 2. nd line Carboplatin pemetrexed 3. rd line Docetaxel
- interventionNames
- Drug: Erlotinib
- type
- ACTIVE_COMPARATOR
- label
- PD-L1 >= 50%
- description
- 1. st line Pembrolizumab 2. nd line Carboplatin pemetrexed 3. rd line Docetaxel
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Stage IIIc or IV Non-small cell lung cancer * Good performance status (ECOG 0-2) * Available tissue for tumor markers * Plan to undergo systemic therapy Exclusion Criteria: * Inadequate cardiac, renal, liver of bone-marrow function * Plan to undergo definitive radiation or curative surgery * Consent withdraw
References
Publications (0)
Data not yet available